The Swiss pharma company Novartis ranks in the top 10 of pharma companies, and boasts drugs ranging from Ritalin and Lamisil to clozapine, Diovan and Gilenya. It also owns the generic giant Sandoz. Unlike its competitor, GlaxoSmithKline, Novartis did not offer free flu vaccines during the H1N1 flu epidemic.

In March 2011, Novartis gained FDA approval for Gilenya, its multiple sclerosis drug. The nod came on the heels of a narrower EMA approval, which grants second-line treatment status. According to experts, the drug could be worth $3 billion in annual sales as the first oral MS drug on the market.

Novartis purchased the remaining portion of eye care company Alcon in a $12.9 billion deal at the end of 2010, marking the end of one of the biggest battles in biopharma. Although many analysts predicted heavy layoffs in 2010 from the company, only 1,400 jobs were cut in December 2010, with the disclaimer that more could be on the way as Novartis, like others in the industry, analyzes its efficiency.

Tag:

Novartis

Latest Headlines

Latest Headlines

The color purple knocks back Novartis' Advair rival in Germany

GlaxoSmithKline's asthma behemoth Advair may be losing ground in Europe, but a legal win may stop some of the bleeding--at least in Germany. The British pharma giant has obtained a preliminary injunction there to stop Novartis' Sandoz from hawking its generic, AirFluSal Forspiro, thanks to the inhaler's purple color.

Eyeing rival mAb mob, Novartis touts PhIII secukinumab psoriasis data

Investigators for Novartis pumped out more positive Phase III data for its psoriasis therapy secukinumab over the weekend, adding some patient satisfaction scores on the self-injected treatment as the company positions this new product against a host of rivals that promise to quickly crowd the field.

Novartis' vaccine unit gets a badly needed booster from the U.K.

The U.K.'s Joint Committee on Vaccination and Immunization (JCVI) is revising its stance on Novartis' meningitis B vaccine Bexsero. The jab, originally left off Britain's routine vaccination schedule, has gained the JCVI's nod, supplying a needed boost for the Swiss company's flailing vaccine unit.

Novartis CEO predicts generic industry fallout as quality takes center stage

Usually, it's the smaller drugmakers that take advantage of opportunities that present themselves when manufacturing problems arise at another company. But Novartis CEO Joe Jimenez is not above trying to drum up some business for his Sandoz generic drug unit by pointing out problems with some of the big drugmakers in India.

Probe finds Novartis not guilty of 'undue influence' at Canadian university eye clinic

Novartis may have helped bring in guest speakers, distributed drug samples, and doled out grants to ophthalmologists affiliated with Western University in Canada, but the company exerted no undue influence on doctors there. That's the conclusion of an independent investigator brought in to check out allegations made by the ophthalmology department's former chair.

Proteon sets out on its own after Novartis waves off a $550M deal

Five years after optioning the right to buy Proteon Therapeutics for up to $550 million, Novartis has walked away from the table despite what Proteon says was a successful study of its blood vessel-dilating drug, leaving the biotech to fend for itself as it prepares for Phase III.

Report: Novartis circles a deal to buy Gamida Cell in $600M deal

Israel's Globes is reporting that Novartis is pursuing a deal to buy out Israel's Gamida Cell for "hundreds of millions" of dollars upfront and hundreds of millions more in milestones, adding up to a total of about $600 million.

Italian prosecutors home in on Roche, Novartis execs in eye-drug collusion probe

Itlaian prosecutors have zeroed in on four executives at Roche and Novartis in their probe of potential fraud in the companies' eye-drug sales, Reuters reports, citing sources. The four executives weren't identified.

Novartis to submit Bexsero to FDA in Q2

The use of Bexsero to quell meningitis B outbreaks at two U.S. universities has given Novartis safety data from 14,000 people, but also convinced the Swiss drugmaker it cannot keep shipping the vaccine under investigational use. Novartis has now outlined its plan to make Bexsero more widely available, starting with a submission to FDA in the second quarter.

Tokyo hospital exec says Novartis employees deeply involved in leukemia-drug trial

Novartis employees were more involved in a Japanese drug study than previously suspected. The University of Tokyo Hospital said doctors not only let Novartis employees collect patient data from various trial sites but also allowed the Swiss drugmaker into its records on all 255 trial participants.